Biocom's program serves to extend effective, well-established and easy-to-perform self-collection nasal swab testing to over 1,300 members across the state under the Food and Drug Administration 's Emergency Use Authorization framework.
Test purchases come equipped with Everlywell Lens, a comprehensive reporting dashboard for human resource representatives, which gives organizations visibility into the status of individual kits, from registration to results.
The program with Everlywell will provide Biocom members access to rt-PCR tests that will determine the presence or absence of RNA from the SARS-CoV-2-virus.
Met with the highest standards of quality, safety, and reliability, Everlywell's straightforward sample collection, free shipping, and physician-reviewed results and insights ensure that we are connecting our members with one of the best testing solutions in the market.
The laboratories used by Everlywell are CLIA-certified and many are CAP-accredited, which means they must meet or exceed high precision, accuracy, and validity standards, obtain both state and federal certifications, and submit themselves to regular inspections as well as independent third-party performance verifications.
Biocom works on behalf of over 1,300 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge workforce development and STEM education programs, and create robust value-driven purchasing programs.
Biocom a public voice for research institutions and life science companies that fuel the California economy.
Biocom Purchasing Group offers member-driven strategic sourcing solutions. Biocom members save on average 15-25x their membership dues through the Biocom Purchasing Group.
In 2019, members collectively saved USD 280m and brought more ideas to market through a broad range of products, services and technologies offered by endorsed Purchasing Group suppliers.
Everlywell connects individuals to certified labs offering a suite of validated lab tests including Cholesterol, Heart Health, Fertility, STIs, Lyme Disease, Testosterone, Thyroid and more, including one of the only FDA-authorized at-home sample collection test kits for COVID-19 and the first at-home sample collection test kits for fertility, high-risk HPV, and indoor and outdoor allergies.
Prices start at USD 49 and tests are generally covered by Flexible Spending and Health Savings Accounts.
The Austin-based company was founded in 2015 and is advised by a Scientific advisory board that includes some of the nation's top scientists from Harvard, MIT, Google and NYU. Everlywell was selected as one of Fast company's Most Innovative Companies in 2019.
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Alvotech and Teva secure US launch date for Eylea biosimilar AVT06
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion